Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

The Fibrinogen to Mean Platelet Volume Ratio Can Predict Overall Survival of Patients with Non-Metastatic Gastric Cancer

  • Song, Shubin (Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital) ;
  • Cong, Xiliang (Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital) ;
  • Li, Fengke (Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital) ;
  • Xue, Yingwei (Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital)
  • Received : 2018.08.15
  • Accepted : 2018.11.22
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Fibrinogen and platelets have been reported to play important roles in tumorigenesis and cancer progression. The aim of this research was to investigate the combination of functions of fibrinogen, platelets, and mean platelet volume (MPV) in predicting the survival of patients with gastric cancer (GC). Materials and Methods: A retrospective study was conducted with 1,946 patients with GC and 299 patients with benign gastric tumor to analyze their fibrinogen, platelet, and MPV levels, and other clinicopathological characteristics along with their prognoses. Several indicators were evaluated along with fibrinogen, platelets, and MPV and their prognostic abilities were assessed. Univariate and multivariate survival analyses were conducted to determine the independent risk factors for overall survival. Results: Increased levels of fibrinogen, platelets, and MPV were observed with the progress of the GC stages. Elevated fibrinogen, platelets, and the combined indicators, including fibrinogen*MPV (FM), platelet*fibrinogen*MPV (PFM), fibrinogen/MPV (FMR), platelet*fibrinogen (PF), platelet*fibrinogen/MPV (PFMR), platelet*MPV (PM), and platelet/MPV (PMR), foreboded poor prognosis. Meanwhile fibrinogen and FMR can be considered as independent risk factors for overall survival in patients with non-metastatic GC. But these indicators can hardly predict survival of patients in stage IV. Conclusions: Elevated fibrinogen, platelets, and MPV levels were in accordance with advanced stages, and fibrinogen, platelet, and MPV, in combination, can be used to predict survival of patients with non-metastatic GC. FMR was an independent prognostic factor for overall survival of patients with GC.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. https://doi.org/10.3322/caac.21332
  2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-132. https://doi.org/10.3322/caac.21338
  3. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-1791. https://doi.org/10.1093/jnci/djg106
  4. Mroczko B, Groblewska M, Łukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin Chem Lab Med 2009;47:1133-1139.
  5. Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci 2009;100:859-865. https://doi.org/10.1111/j.1349-7006.2009.01115.x
  6. Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 2013;8:e73609. https://doi.org/10.1371/journal.pone.0073609
  7. Yu X, Hu F, Yao Q, Li C, Zhang H, Xue Y. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study. BMC Cancer 2016;16:480. https://doi.org/10.1186/s12885-016-2510-z
  8. Lian L, Xia YY, Zhou C, Shen XM, Li XL, Han SG, et al. Mean platelet volume predicts chemotherapy response and prognosis in patients with unresectable gastric cancer. Oncol Lett 2015;10:3419-3424. https://doi.org/10.3892/ol.2015.3784
  9. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000;45:23-41. https://doi.org/10.1016/S0167-5877(00)00115-X
  10. Suzuki T, Shimada H, Nanami T, Oshima Y, Yajima S, Ito M, et al. Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patients with gastric cancer. Surg Today 2016;46:1394-1401. https://doi.org/10.1007/s00595-016-1339-z
  11. Song S, Li C, Li S, Gao H, Lan X, Xue Y. Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer. Onco Targets Ther 2017;10:3145-3154. https://doi.org/10.2147/OTT.S138039
  12. Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer 2014;83:97-101. https://doi.org/10.1016/j.lungcan.2013.08.020
  13. Kurt M, Onal IK, Sayilir AY, Beyazit Y, Oztas E, Kekilli M, et al. The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 2012;59:1580-1582.
  14. Zhu LR, Li J, Chen P, Jiang Q, Tang XP. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clin Transl Oncol 2016;18:178-188. https://doi.org/10.1007/s12094-015-1350-7
  15. Sheng L, Luo M, Sun X, Lin N, Mao W, Su D. Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer. Int J Cancer 2013;133:2720-2725.
  16. Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Takahashi T, et al. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol 2015;22:302-310. https://doi.org/10.1245/s10434-014-3857-5
  17. Mei Y, Zhao S, Lu X, Liu H, Li X, Ma R. Clinical and prognostic significance of preoperative plasma fibrinogen levels in patients with operable breast cancer. PLoS One 2016;11:e0146233. https://doi.org/10.1371/journal.pone.0146233
  18. Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol 1998;28:740-744. https://doi.org/10.1093/jjco/28.12.740
  19. Mikami J, Kurokawa Y, Takahashi T, Miyazaki Y, Yamasaki M, Miyata H, et al. Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study. Gastric Cancer 2016;19:817-826. https://doi.org/10.1007/s10120-015-0556-2
  20. Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 2003;9:383-390.
  21. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178-185. https://doi.org/10.1182/blood-2004-06-2272
  22. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-134. https://doi.org/10.1038/nrc3004
  23. Yu LX, Yan L, Yang W, Wu FQ, Ling Y, Chen SZ, et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nat Commun 2014;5:5256. https://doi.org/10.1038/ncomms6256
  24. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494. https://doi.org/10.1056/NEJMra071014
  25. Oge T, Yalcin OT, Ozalp SS, Isikci T. Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstet Gynaecol 2013;33:301-304. https://doi.org/10.3109/01443615.2012.758089

Cited by

  1. Clinicopathological and prognostic value of preoperative plasma fibrinogen in gastric cancer patients : A meta-analysis vol.98, pp.40, 2019, https://doi.org/10.1097/md.0000000000017310
  2. Association of prealbumin/fibrinogen ratio with clinicopathologic characteristics of gastric cancer vol.27, pp.18, 2018, https://doi.org/10.11569/wcjd.v27.i18.1133
  3. Preoperative platelet counts and postoperative outcomes in cancer surgery: a multicenter, retrospective cohort study vol.31, pp.1, 2018, https://doi.org/10.1080/09537104.2019.1573977
  4. ELF3‐AS1 contributes to gastric cancer progression by binding to hnRNPK and induces thrombocytosis in peripheral blood vol.112, pp.11, 2018, https://doi.org/10.1111/cas.15104